ACADIA\'s pimavanserin misses main goal of Phase III study as adjunctive treatment in schizophrenia; shares fall httpbit.ly2GofhqCÂ pharma

ACADIA's pimavanserin misses main goal of Phase III study as adjunctive treatment in schizophrenia; shares fall http://bit.ly/2GofhqC  #pharma

19:53 EDT 22 Jul 2019 | FirstWord Pharma

ACADIA's pimavanserin misses main goal of Phase III study as adjunctive treatment in schizophrenia; shares fall http://bit.ly/2GofhqC  #pharma

More From BioPortfolio on "ACADIA's pimavanserin misses main goal of Phase III study as adjunctive treatment in schizophrenia; shares fall http://bit.ly/2GofhqC  #pharma"